Roche's Petrelintide Hits 10.7% Weight Loss in Phase II ZUPREME-1 Trial – Amylin Analog Shows Sustained Efficacy Through Week 42

Roche (SWX: ROG, OTCMKTS: RHHBY) announced positive topline results from the Phase II ZUPREME-1 trial evaluating petrelintide in 493 individuals with overweight and obesity (mean BMI 37 kg/m²). Participants achieved up to 10.7% mean weight loss from baseline at week 42 versus 1.7% placebo, demonstrating sustained efficacy for the once-weekly amylin analog acquired through the 2025 Zealand Pharma partnership.

Contents

Clinical Trial Results
Drug Profile & Mechanism
Strategic Partnership Context
Competitive Positioning & Market Impact
Development Outlook

- Advertisement -

Clinical Trial Results

Endpoint	Petrelintide	Placebo	Treatment Effect
Mean Weight Loss (Week 42)	Up to 10.7%	1.7%	9.0 percentage-point advantage
Analysis Method	Efficacy estimand	—	Accounts for treatment adherence
Study Population	493 participants	—	Mean BMI 37 kg/m² (obese)
Duration	42 weeks	—	Sustained weight loss trend
Trial Name	ZUPREME-1 (Phase II)	—	Randomized, double-blind, placebo-controlled

Drug Profile & Mechanism

Attribute	Petrelintide Profile
Drug Class	Long-acting amylin analog
Target	Amylin receptor (co-localized with calcitonin receptor in brainstem)
Mechanism	Restores leptin sensitivity → enhanced satiety signaling; slows gastric emptying
Dosing	Once-weekly subcutaneous injection
Physiological Role	Mimics pancreatic beta-cell amylin co-secreted with insulin post-prandially
Differentiation	Novel satiety pathway vs. GLP-1/GIP incretins; potential for complementary/combination use

Strategic Partnership Context

Element	Detail
Partner	Zealand Pharma (exclusive collaboration)
Agreement Date	2025
Structure	Co-development and co-commercialization
Roche Contribution	Global clinical development infrastructure; commercial scale
Zealand Contribution	Amylin peptide engineering expertise; IP estate
Therapeutic Focus	Overweight and obesity (initial); potential expansion to metabolic syndrome

Competitive Positioning & Market Impact

Factor	Strategic Implication
Efficacy Benchmark	10.7% weight loss positions petrelintide competitively vs. early-phase GLP-1 data (semaglutide Phase II: ~12-15%)
Differentiation	Amylin mechanism offers alternative for GLP-1 intolerant patients; potential for fixed-dose combination with incretins
Safety Profile	Amylin analogs historically associated with lower GI side effects vs. GLP-1s; nausea/vomiting rates critical for Phase III design
Market Timing	Phase III initiation expected 2026; potential 2028-2029 launch amid GLP-1 market maturation
Revenue Potential	Analysts estimate $5-10 billion peak sales if approved as monotherapy or combination; Zealand Pharma milestone/royalty structure

Development Outlook

Phase III Design: Head-to-head vs. GLP-1 expected; combination arm with Roche’s internal incretin assets under evaluation
Combination Strategy: Amylin + GLP-1 co-agonism (tirzepatide-like efficacy with improved tolerability) represents next-generation obesity pharmacotherapy
Manufacturing: Peptide-based production scalable; Roche’s biologics capacity supports global supply
Regulatory Pathway: FDA Breakthrough Therapy designation potential given unmet need and novel mechanism

Forward‑Looking Statements
This brief contains forward‑looking statements regarding Phase III development timelines, regulatory pathways, and commercial potential for petrelintide. Actual results may differ due to competitive dynamics, safety findings in larger trials, and reimbursement decisions.-Fineline Info & Tech

Roche’s Petrelintide Hits 10.7% Weight Loss in Phase II ZUPREME-1 Trial – Amylin Analog Shows Sustained Efficacy Through Week 42

Clinical Trial Results

Drug Profile & Mechanism

Strategic Partnership Context

Competitive Positioning & Market Impact

Development Outlook

You May also Like

Keymed Biosciences’ Stapokibart Receives First Prescription in China for IL-4Rα Targeting Therapy

Bayer Announces Consumer Health Leadership Restructuring with New Global and U.S. Appointments

Kintor Pharmaceutical’s KX-826 Shows Promising Results in Phase III AGA Clinical Trial

SciClone Pharmaceuticals Teams Up with SPH Health and Hi Dr to Launch Internet Hospital in China

About Company